Matthew A Lakins

Publication Activity (10 Years)

Years Active: 2024-2024
Publications (10 Years): 4

Top Topics

Immune Response

Endoplasmic Reticulum Stress

Top Venues

Cancer research communications

This page only lists publications with an associated author ORCID identifier.

Publications

Charlotte J Imianowski, Paula Kuo, Sarah K Whiteside, Teresa von Linde, Alexander J Wesolowski, Alberto G Conti, Alexander C Evans, Tarrion Baird, Benjamin I Morris, Nicole E Fletcher, Jie Yang, Edmund Poon, Matthew A Lakins, Masahiro Yamamoto, Neil Brewis, Michelle Morrow, Rahul Roychoudhuri
IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy. Cancer research communications 4 (8) (2024)
Charlotte J Imianowski, Paula Kuo, Sarah K Whiteside, Teresa von Linde, Alexander J Wesolowski, Alberto G Conti, Alexander C Evans, Tarrion Baird, Benjamin I Morris, Nicole E Fletcher, Jie Yang, Edmund Poon, Matthew A Lakins, Masahiro Yamamoto, Neil Brewis, Michelle Morrow, Rahul Roychoudhuri
IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy. Cancer research communications 4 (8) (2024)
Charlotte J Imianowski, Paula Kuo, Sarah K Whiteside, Teresa von Linde, Alexander J Wesolowski, Alberto G Conti, Alexander C Evans, Tarrion Baird, Benjamin I Morris, Nicole E Fletcher, Jie Yang, Edmund Poon, Matthew A Lakins, Masahiro Yamamoto, Neil Brewis, Michelle Morrow, Rahul Roychoudhuri
IFN-γ production by functionally reprogrammed Treg cells promotes anti-tumor efficacy of OX40/CD137 bispecific agonist therapy. Cancer research communications (2024)
Charlotte J Imianowski, Paula Kuo, Sarah K Whiteside, Teresa von Linde, Alexander J Wesolowski, Alberto G Conti, Alexander C Evans, Tarrion Baird, Benjamin I Morris, Nicole E Fletcher, Jie Yang, Edmund Poon, Matthew A Lakins, Masahiro Yamamoto, Neil Brewis, Michelle Morrow, Rahul Roychoudhuri
IFNγ Production by Functionally Reprogrammed Tregs Promotes Antitumor Efficacy of OX40/CD137 Bispecific Agonist Therapy. Cancer research communications 4 (8) (2024)